Themis Bioscience
Muthgasse 11/2
Vienna
1190
Tel: 43-1-236-7151
Fax: 43-1-236-7151-74
Website: http://www.themisbio.com/
About Themis Bioscience
Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications.LEADERSHIP:
Founder and CEO: Erich Tauber
CFO: David A. Maier
CLINICAL TRIAL:
Please click here for clinical trial information.
29 articles with Themis Bioscience
-
Themis Release: Chikungunya Vaccine Development Towards Phase III Trials Boosted By Innovate UK
9/5/2017
-
Chikungunya-Fever: Themis Starts Phase II Clinical Study In Endemic Area
7/27/2017
-
Zika Virus: Themis Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine
4/11/2017
-
Themis Successfully Closes 10 Million Eur Financing Round
11/28/2016
-
Themis Release: Zika Vaccine Development Receives Big Boost By Innovate UK
9/6/2016
-
Themis: Phase 2 Trial Of Leading Chikungunya Vaccine Candidate Started
8/25/2016
-
Two Renowned Vaccine Experts Joining Themis
1/19/2016
-
Themis’s Raises Up To EUR 10 Million In Series B
5/5/2015
-
Themis’s Chikungunya Vaccine Study Results Published In The Lancet Infectious Diseases
3/2/2015